Article
Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.
Molecular cancer therapeutics - 1 May 2016
Mu Chaofeng, Wu Xiaoyan, Ma Helen, Tao Wenjing, Zhang Guodong, Xia Xiaojun, Shen Jianliang, Mai Junhua, Sun Tong, Sun Xiaoping, Arlinghaus Ralph B, Shen Haifa
Abstract excerpt
Leukemia cells escape BCR-ABL-targeted therapy by developing mutations, such as T315I, in the p210(BCR-ABL) fusion protein in Philadelphia chromosome-positive chronic myeloid leukemia (CML). Although most effort has been focused on development of new tyrosine kinase inhibitors, enrichment of these small-molecule inhibitors in the tumor tissue can also have a profound impact on treatment outcomes. Here, we report...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.